Loyd India, Papac Nicole, Hirshburg Jason, Levin Jarad, Dannelley Jennifer, Dorris Janislynn, Stratton Jason, Mehdi Nighat
College of Medicine (IL), University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Department of Dermatology (NP, JH, JL), University of Oklahoma Health Sciences Center, Oklahoma City, OK.
J Pediatr Pharmacol Ther. 2022;27(5):467-469. doi: 10.5863/1551-6776-27.5.467. Epub 2022 Jul 6.
Adverse reactions, including severe cutaneous reactions, to cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been described in the literature. Herein we present a drug eruption in response to elexacaftor/tezcaftor/ivacaftor (brand name, Trikafta) in a 7-year-old male with cystic fibrosis, followed by desensitization and successful continuation. A review of the literature outlining similar cases is provided. Attempting to mitigate and manage drug reactions to CFTR modulators is essential because they represent vital and irreplaceable therapies for individuals with cystic fibrosis (CF).
文献中已描述了囊性纤维化跨膜传导调节因子（CFTR）调节剂的不良反应，包括严重的皮肤反应。在此，我们报告了一名7岁囊性纤维化男性患者在使用依列卡福/特扎卡福/依伐卡福（商品名，Trikafta）后出现的药疹，随后进行了脱敏并成功继续用药。本文还提供了对概述类似病例的文献综述。尝试减轻和管理对CFTR调节剂的药物反应至关重要，因为它们是囊性纤维化（CF）患者至关重要且不可替代的治疗方法。
